Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,730 recruiting studies in this area right now.
By phase
- Not applicable9,856
- Phase 24,487
- Phase 12,738
- Phase 1/Phase 21,696
- Phase 31,409
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,233
- Prostate Cancer660
- Cancer655
- Colorectal Cancer499
- Lung Cancer430
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer302
- Pancreatic Cancer295
- Acute Myeloid Leukemia290
- Hepatocellular Carcinoma285
- Solid Tumor256
- Advanced Solid Tumor254
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer207
- Advanced Solid Tumors196
- Esophageal Cancer196
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University317
- National Cancer Institute (NCI)291
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center146
- AstraZeneca131
- University Health Network, Toronto125
Where studies are running
- California1,432
- Texas644
- Arizona514
- Florida437
- Alabama419
- New York410
- Massachusetts342
- Maryland331
- New Jersey267
- Pennsylvania237
Recruiting studies20,730 total
- NCT06644430Recruiting
Burning lung spots plus systemic therapy for liver cancer
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Beijing, Beijing MunicipalityAges 18–80 - NCT06644560Recruiting
Diet and exercise before cancer treatment
This study tests if a program of eating walnuts and doing light exercise before starting cancer treatment can help reduce inflammation in the body. It is for people being treated at San Carlos Apache Healthcare Corporation.
Tucson, ArizonaAges 18–80 - NCT06644625Recruiting
CHAAMP study: MGUS screening for Black adults and relatives
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
Charlotte, North CarolinaAges 30 years+ - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
Boston, MassachusettsAges 18 years+ - NCT06644846Recruiting
Spaced radiation for gynecologic cancers
This trial tests a special type of radiation that is given in small, spaced-out beams to treat gynecologic cancers (like cervical or uterine cancer). It is for patients who cannot get standard internal radiation (brachytherapy) because of unusual anatomy, large tumors, a narrow vagina, or anesthesia risks.
Navi Mumbai, MaharashtraAges 18–70 - NCT06644937RecruitingPhase 2/Phase 3
TACE with Icaritin after surgery for high-risk liver cancer
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06645236Recruiting
Testing for a specific KRAS mutation in tumor tissue
This study tests your tumor tissue for a specific change in the KRAS gene called G12C. Finding this mutation may help guide treatment options for certain cancers.
Manchester, ManchesterAges 18 years+ - NCT06645678RecruitingPhase 1/Phase 2
Mezigdomide and Elranatamab for relapsed or hard-to-treat multiple myeloma
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
SingaporeAges 19 years+ - NCT06645808RecruitingEarly Phase 1
PET imaging study for various solid tumors
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
Groningen, Provincie GroningenAges 18 years+ - NCT06645951Recruiting
Italian database study for parathyroid cancer or atypical adenoma
This study is building a database of patients with parathyroid carcinoma or atypical parathyroid adenoma. By gathering information, doctors hope to learn more about these rare tumors and improve care for future patients.
BariAges Any age - NCT06646341Recruiting
Can scan findings predict colorectal cancer spread?
This study looks at whether signs of blood vessel involvement (called EMVI) seen on scans can predict if colorectal cancer spreads to other organs. You might join if you already had surgery to remove the cancer from the colon or rectum and any distant tumors, and your before-surgery scans are available for review.
Basingstoke, HampshireAges 16–100 - NCT06646471RecruitingPhase 4
Study of cancer drugs for older adults with lung cancer
This trial tests approved cancer drugs in people aged 70 and older with non-small-cell lung cancer who haven't had systemic treatment before. The goal is to see how well these drugs work in this older population.
Aix-en-ProvenceAges 70 years+ - NCT06646588RecruitingPhase 2
Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT06646809RecruitingPhase 3
Reducing inflammation after colorectal cancer surgery trial
This trial tests a way to reduce inflammation after planned colorectal cancer surgery. It may help you recover better and have fewer complications.
Singapore, SingaporeAges 45 years+ - NCT06647680RecruitingPhase 2
Chemo and immunotherapy before surgery for rectal cancer
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Qingdao, ShandongAges 18–75 - NCT06647862RecruitingPhase 3
Testing a new drug combo for newly diagnosed CMML
This trial tests whether adding the experimental drug IMM01 to standard azacitidine works better than azacitidine alone for people with chronic myelomonocytic leukemia (CMML). The goal is to see if the combination can help control the disease with manageable side effects.
Hefei, AnhuiAges 18 years+ - NCT06647901RecruitingPhase 1/Phase 2
ICG dye imaging for giant cell tumor surgery
This trial uses a special dye (ICG) and a camera to help surgeons see the tumor better during surgery for giant cell tumors of bone in the arms or legs. The goal is to remove all of the tumor while saving as much healthy bone as possible.
Beijing, Beijing MunicipalityAges 18–65 - NCT06647940RecruitingPhase 2
Orelabrutinib plus R-CHOP for CD5-positive DLBCL
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
Guangzhou, ChinaAges 18 years+ - NCT06648096RecruitingPhase 1/Phase 2
Testing afatinib for head and neck cancer in Fanconi anemia patients
This trial tests whether the targeted drug afatinib can shrink advanced head and neck cancers in people who also have Fanconi anemia. It is for patients whose tumors cannot be surgically removed and have not responded to or cannot have other standard treatments.
HanoverAges 18 years+ - NCT06648057Recruiting
Predictors of response in biliary tract cancer
This trial is looking at how certain markers in your blood or tissue (biomarkers) might predict how well the combination of Lenvatinib and Pembrolizumab works against advanced biliary tract cancer. If you're already scheduled to receive these two drugs, researchers want to learn more from your samples to help future patients.
Seongnam-si, Gyeonggi-doAges 20 years+ - NCT06648148Recruiting
Molecular markers for radiation response in breast cancer
This trial looks for biomarkers (biological signs) in breast tissue that might predict how well breast cancer responds to radiation therapy. It is for patients with ductal carcinoma in situ (DCIS) who are scheduled to receive radiation after surgery.
LjubljanaAges 18–75 - NCT06648278Recruiting
Support and technology study for breast cancer patients
This trial tests a program called PONTS 2.0 that uses phone texts and online tools to support breast cancer patients through their treatment. It aims to make it easier for patients to get the help they need.
San Francisco, CaliforniaAges 18 years+ - NCT06648317Recruiting
New PET scan for lung tumors using a Nectin-4 probe
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06648434RecruitingPhase 1
MK2 inhibitor plus mFOLFIRINOX for metastatic pancreatic cancer
This trial tests an experimental drug called zunsemetinib (an MK2 inhibitor) combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with pancreatic cancer that has spread to other organs. The goal is to see if the combination works better than chemotherapy alone.
St Louis, MissouriAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,730 recruiting oncology studies from the U.S. registry right now, out of 32,266 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.